Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • NPPA sets retail...

NPPA sets retail prices for 41 drugs, including 29 Fixed-Dose Combinations containing Empagliflozin or Sitagliptin

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-06-05T16:05:50+05:30  |  Updated On 5 Jun 2025 4:10 PM IST
NPPA sets retail prices for 41 drugs, including 29 Fixed-Dose Combinations containing Empagliflozin or Sitagliptin
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: In its 133rd meeting held on May 29, 2025, the National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 41 drug formulations under the Drugs (Prices Control) Order, 2013.

Among these, 29 of these formulations are anti-diabetic fixed-dose combinations (FDCs) involving the widely prescribed agents Empagliflozin and Sitagliptin. These include:

. 18 Empagliflozin-based combinations, with prices ranging from Rs 9.90 to Rs 33.13 per tablet.

. 11 Sitagliptin-based combinations (with Glimepiride and Metformin), all priced between Rs 12.82 and Rs 14.50 per tablet.

The price control move targets widely prescribed anti-diabetic fixed-dose combinations, manufactured and marketed by companies including Zydus Healthcare, USV, Emcure Pharma, Alkem Labs, Glenmark Pharma, and Torrent Pharma.

Apart from anti-diabetic combinations, NPPA also fixed retail prices for several other essential formulations, including Atorvastatin & Ezetimibe tablets for dyslipidemia, Ceftriaxone, Sulbactam & Disodium Edetate Powder for solution for Infusion for bacterial infections, Cholecalciferol oral drops for vitamin D deficiency, Melatonin & Zolpidem Tartrate tablets for sleep disorders, and Alginate Raft-Forming Oral Suspension for acid reflux. The move aims to ensure affordability of essential therapies across diverse therapeutic areas including cardiovascular, gastrointestinal, infectious diseases, and respiratory care. The retail prices are exclusive of GST.

Sl. No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1

Alginate Raft- Forming Oral Suspension

Each 5 ml contains:

Sodium Alginate IP 250 mg

Sodium Bicarbonate IP 133.5 mg

Calcium Carbonate IP 80 mg

1 ml

M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Apex Laboratories Pvt. Ltd.

0.93

2

Atorvastatin & Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP equivalent to Atorvastatin 10mg

Ezetimibe IP 10mg

1 Tablet

M/s Safetab Life Science/ M/s Ajanta Pharma Ltd.

19.66

3

Atorvastatin & Ezetimibe Tablets

Each film coated tablet contains:

Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg

Ezetimibe IP 10mg

1 Tablet

M/s Windlas Biotech Ltd./ M/s Zydus Healthcare Ltd.

54.29

4

Ceftriaxone, Sulbactam & Disodium Edetate Powder for solution for Infusion

Each vial contains:

Ceftriaxone Sodium IP eq. to Ceftriaxone 1000 mg

Disodium Edetate IP 37 mg

Sulbactam Sodium IP eq. Sulbactam 500 mg

1 vial

M/s BDR Pharma- ceuticals International Pvt. Ltd./ M/S Glenmark Pharma-ceuticals Ltd.

515.57

5

Cefuroxime & Potassium Clavulanate Tablets

Each film coated tablet contains:

Cefuroxime Axetil IP eq. to Cefuroxime 500 mg

Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg

1 Tablet

M/s Supermax Drugs & Pharmaceuticals Pvt. Ltd./ M/s Profic Organic Ltd.

60.62

6

Cholecalciferol Oral Drops

Each ml of Suspension contains:

Vitamin D3 IP 800 IU

1 ml

M/s Stedman Pharmaceuticals Pvt. Ltd.

4.76

7

Clindamycin & Nicotinamide gel

Clindamycin Phosphate IP eq. to Clindamycin 1.00% w/w Nicotinamide IP 4.00% w/w

1 gm

M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.

7.24

8

Iron, Folic Acid & Cyanocobalamin Syrup

Each 5 ml contains:

Ferric Ammonium Citrate IP 110 mg

Folic Acid IP 1.5 mg

Cyanocobalamin IP 15 mcg

Sorbitol (70%) (Non- Crystallising)

1 ml

M/s East African (I) Overseas / M/s Mankind Prime Labs Pvt. Ltd.

0.23

9

Melatonin & Zolpidem Tartrate Tablets

Each film coated tablet contains:

Melatonin BP 3 mg

Zolpidem Tartrate IP 5 mg

1 Tablet

M/s Windlas Biotech Ltd./

M/s Ipca Laboratories Ltd.

6.62

10

Melatonin & Zolpidem Tartrate Tablets

Each film coated tablet contains:

Melatonin BP 3 mg

Zolpidem Tartrate IP 10 mg

1 Tablet

M/s Windlas Biotech Ltd./

M/s Ipca Laboratories Ltd.

8.73

11

Polmacoxib & Paracetamol Tablets

Each uncoated tablet contains:

Polmacoxib IH 2 mg

Paracetamol IP 325 mg

1 Tablet

M/s Hetero Labs Ltd./ M/s Zuventus Healthcare Ltd.

15.39

12

Empagliflozin & Metformin Hydrochloride (ER) Tablets

Each film coated bilayered tablet contains:

Empagliflozin 10mg

Metformin Hydrochloride 1000mg (as extended release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.

9.90

13

Empagliflozin & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Empagliflozin 12.5 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Unison Pharmaceuticals Pvt. Ltd.

18.10

14

Empagliflozin & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Empagliflozin 12.5 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Zydus Healthcare Ltd.

18.10

15

Empagliflozin & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Empagliflozin 12.5 mg

Metformin Hydrochloride IP 1000 mg

1 Tablet

M/s Unison Pharmaceuticals Pvt. Ltd.

19.01

16

Empagliflozin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 12.5 mg

Metformin Hydrochloride IP 1000 mg (as Extended release)

1 Tablet

M/s MSN Laboratories Pvt. Ltd.

17.86

17

Empagliflozin & Metformin Hydrochloride (ER) Tablets

Each film coated bilayered tablet contains:

Empagliflozin 25 mg

Metformin Hydrochloride IP 1000 mg (as extended release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.

11.70

18

Empagliflozin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg

Metformin Hydrochloride IP 1000 mg (as Extended release)

1 Tablet

M/s MSN Laboratories Pvt. Ltd.

18.75

19

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 10 mg

Linagliptin 5 mg

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Zydus Healthcare Ltd.

29.08

20

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 10 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.

29.08

21

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 10 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Glenmark Pharmaceuticals Ltd.

29.08

22

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 10 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd.

28.57

23

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 10 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.

17.50

24

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Zydus Healthcare Ltd.

33.13

25

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd.

32.43

26

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated bilayer tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd.

33.13

27

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP

1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Glenmark Pharmaceuticals Ltd.

33.13

28

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd.

30.36

29

Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated tablet contains:

Empagliflozin 25 mg,

Linagliptin 5 mg,

Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd.

19.50

30

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 1 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s USV Private Ltd.

12.82

31

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 1 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd.

12.82

32

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 1 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Alkem Laboratories Ltd.

12.82

33

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 1 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Dr. Reddys Laboratories Ltd.

12.82

34

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 1 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Zydus Healthcare Ltd.

12.82

35

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s USV Private Ltd.

14.50

36

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd.

14.50

37

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Alkem Laboratories Ltd.

14.50

38

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Eris Lifesciences Ltd.

14.50

39

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Dr. Reddys Laboratories Ltd.

14.50

40

Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets

Each film coated tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg

Glimepiride IP 2 mg

Metformin Hydrochloride IP 500 mg

1 Tablet

M/s Exemed Pharmaceuticals/

M/s Zydus Healthcare Ltd.

14.50

41

Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup

Each 5 ml contains:

Phenylephrine Hydrochloride IP 5 mg

Chlorpheniramine Maleate IP 2 mg

1 ml

M/s Vapi Care Pharma Pvt. Ltd. /

M/s Apex Laboratories Pvt. Ltd.

1.01

Note:

(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

For complete product-wise details, refer to official notification.


NPPAempagliflozinsitagliptinglimepiridemetforminzydus HealthcareUSVemcure pharmaalkem labsglenmark pharmatorrent pharmaparacetamollinagliptin
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI: EuroPCR 2025 Update

    ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI:...

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    View All

    Journal Club Today

    Study Unveils Molecular Links between Air Pollution and Negative Birth Outcomes

    Study Unveils Molecular Links between Air Pollution and Negative Birth Outcomes

    View All

    Health News Today

    Health Bulletin 05/June/2025

    Health Bulletin 05/June/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok